Literature DB >> 19327047

Appreciating HIV type 1 diversity: subtype differences in Env.

Rebecca M Lynch1, Tongye Shen, S Gnanakaran, Cynthia A Derdeyn.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) group M is responsible for the current AIDS pandemic and exhibits exceedingly high levels of viral genetic diversity around the world, necessitating categorization of viruses into distinct lineages, or subtypes. These subtypes can differ by around 35% in the envelope (Env) glycoproteins of the virus, which are displayed on the surface of the virion and are targets for both neutralizing antibody and cell-mediated immune responses. This diversity reflects the remarkable ability of the virus to adapt to selective pressures, the bulk of which is applied by the host immune response, and represents a serious obstacle for developing an effective vaccine with broad coverage. Thus, it is important to understand the underlying biological consequences of intersubtype diversity. Recent studies have revealed that some of the HIV-1 subtypes exhibit phenotypic differences stemming from subtle changes in Env structure, particularly within the highly immunogenic V3 domain, which participates directly in viral entry. This review will therefore explore current research that describes subtype differences in Env at the genetic and phenotypic level, focusing in particular on V3, and highlighting recent discoveries about the unique features of subtype C Env, which is the most globally prevalent subtype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19327047      PMCID: PMC2853864          DOI: 10.1089/aid.2008.0219

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  123 in total

Review 1.  Genetic diversity of HIV in Africa: impact on diagnosis, treatment, vaccine development and trials.

Authors:  Martine Peeters; Coumba Toure-Kane; John N Nkengasong
Journal:  AIDS       Date:  2003-12-05       Impact factor: 4.177

2.  Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.

Authors:  Cynthia A Derdeyn; Julie M Decker; Frederic Bibollet-Ruche; John L Mokili; Mark Muldoon; Scott A Denham; Marintha L Heil; Francis Kasolo; Rosemary Musonda; Beatrice H Hahn; George M Shaw; Bette T Korber; Susan Allen; Eric Hunter
Journal:  Science       Date:  2004-03-26       Impact factor: 47.728

3.  Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.

Authors:  M Tersmette; J M Lange; R E de Goede; F de Wolf; J K Eeftink-Schattenkerk; P T Schellekens; R A Coutinho; J G Huisman; J Goudsmit; F Miedema
Journal:  Lancet       Date:  1989-05-06       Impact factor: 79.321

4.  The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.

Authors:  Abraham Pinter; William J Honnen; Yuxian He; Miroslaw K Gorny; Susan Zolla-Pazner; Samuel C Kayman
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

5.  Development of the antibody response in acute HIV-1 infection.

Authors:  Marlén M I Aasa-Chapman; Anna Hayman; Philippa Newton; David Cornforth; Ian Williams; Persephone Borrow; Peter Balfe; Aine McKnight
Journal:  AIDS       Date:  2004-02-20       Impact factor: 4.177

6.  Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.

Authors:  Marintha L Heil; Julie M Decker; Jeffrey N Sfakianos; George M Shaw; Eric Hunter; Cynthia A Derdeyn
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

7.  Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.

Authors:  Shawn E Kuhmann; Pavel Pugach; Kevin J Kunstman; Joann Taylor; Robyn L Stanfield; Amy Snyder; Julie M Strizki; Janice Riley; Bahige M Baroudy; Ian A Wilson; Bette T Korber; Steven M Wolinsky; John P Moore
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

8.  Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: further evidence of broad HIV type 1 genetic diversity.

Authors:  Ping Zhong; Sherri BUrda; Frank Konings; Mateusz Urbanski; Liying Ma; Leopold Zekeng; Leonard Ewane; Lucy Agyingi; Moise Agwara; Ze E Afane; Thompson Kinge; Susan Zolla-Pazner; Phillipe Nyambi
Journal:  AIDS Res Hum Retroviruses       Date:  2003-12       Impact factor: 2.205

9.  Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20.

Authors:  Tonie Cilliers; Trudy Patience; Candice Pillay; Maria Papathanasopoulos; Lynn Morris
Journal:  AIDS Res Hum Retroviruses       Date:  2004-05       Impact factor: 2.205

10.  Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes.

Authors:  Marc Choisy; Christopher H Woelk; Jean-François Guégan; David L Robertson
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more
  42 in total

1.  Inference of global HIV-1 sequence patterns and preliminary feature analysis.

Authors:  Yan Wang; Reda Rawi; Daniel Hoffmann; Binlian Sun; Rongge Yang
Journal:  Virol Sin       Date:  2013-07-27       Impact factor: 4.327

2.  Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.

Authors:  Karen A Kirby; Yee Tsuey Ong; Atsuko Hachiya; Thomas G Laughlin; Leslie A Chiang; Yun Pan; Jennifer L Moran; Bruno Marchand; Kamalendra Singh; Fabio Gallazzi; Thomas P Quinn; Kazuhisa Yoshimura; Toshio Murakami; Shuzo Matsushita; Stefan G Sarafianos
Journal:  FASEB J       Date:  2014-10-28       Impact factor: 5.191

3.  A Universal CAR-NK Cell Targeting Various Epitopes of HIV-1 gp160.

Authors:  Rebecca M Lim; Liang Rong; Anjie Zhen; Jianming Xie
Journal:  ACS Chem Biol       Date:  2020-07-28       Impact factor: 5.100

4.  Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry.

Authors:  Lamorris M Loftin; Martha F Kienzle; Yanjie Yi; Benhur Lee; Fang-Hua Lee; Lachlan Gray; Paul R Gorry; Ronald G Collman
Journal:  Virology       Date:  2010-04-09       Impact factor: 3.616

5.  Donor and recipient envs from heterosexual human immunodeficiency virus subtype C transmission pairs require high receptor levels for entry.

Authors:  Melissa Alexander; Rebecca Lynch; Joseph Mulenga; Susan Allen; Cynthia A Derdeyn; Eric Hunter
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

6.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

7.  Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals.

Authors:  Charmaine P Mutucumarana; Joshua Eudailey; Erin P McGuire; Nathan Vandergrift; Gerald Tegha; Charles Chasela; Sascha Ellington; Charles van der Horst; Athena P Kourtis; Sallie R Permar; Genevieve G Fouda
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

8.  HIV-1 Populations in Semen Arise through Multiple Mechanisms.

Authors:  Jeffrey A Anderson; Li-Hua Ping; Oliver Dibben; Cassandra B Jabara; Leslie Arney; Laura Kincer; Yuyang Tang; Marcia Hobbs; Irving Hoffman; Peter Kazembe; Corbin D Jones; Persephone Borrow; Susan Fiscus; Myron S Cohen; Ronald Swanstrom
Journal:  PLoS Pathog       Date:  2010-08-19       Impact factor: 6.823

9.  HIV-1 subtype C envelope characteristics associated with divergent rates of chronic disease progression.

Authors:  Derseree Archary; Michelle L Gordon; Taryn N Green; Hoosen M Coovadia; Philip J R Goulder; Thumbi Ndung'u
Journal:  Retrovirology       Date:  2010-11-04       Impact factor: 4.602

10.  Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways.

Authors:  Rong Rong; Bing Li; Rebecca M Lynch; Richard E Haaland; Megan K Murphy; Joseph Mulenga; Susan A Allen; Abraham Pinter; George M Shaw; Eric Hunter; James E Robinson; S Gnanakaran; Cynthia A Derdeyn
Journal:  PLoS Pathog       Date:  2009-09-18       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.